ClinCapture announces AI-powered clinical trial build tech that automates study configuration, and advances intelligent ...

The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.

IQVIA Holdings Inc. (NYSE:IQV) is one of the 11 Best Affordable Growth Stocks to Buy Now. On March 3, analysts at RBC Capital initiated coverage of IQVIA Holdings Inc. (NYSE:IQV) with an Outperform ...

Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster ...

“Our partnership with CRIO accelerates our strategy connecting site-level eSource and the Medidata Platform,” said Tom Doyle, chief technology officer, Medidata. “This will accelerate workflows for ...

Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...

Navigating today’s rapidly evolving clinical trial landscape can be tough. With intricate protocols and shifting regulatory demands, it’s more difficult than ever to find and keep participants, as ...

MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...

New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures The research assesses how protocol design ...

Ruthie Davi, vice president of statistics and regulatory innovation at Medidata, highlights the value of technology in rare ...